DocDollars

Innocoll Pharmaceuticals Limited

NJ · United States · Reporting entity ID 100000961852

Total reported 2019–2025
$14.9M
#392 of 2,960 reporting companies — 0% of all reported industry payments
$368K in general payments across 3,777 records, plus $14.5M in research funding across 121 records.

How it breaks down

General payments $367,664
Research funding $14,503,800

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Innocoll Pharmaceuticals Limited reported $14.9M to US doctors and teaching hospitals from 2019 to 2025, ranking #392 of 2,960 reporting companies. 98% of that was research funding and 2% general payments such as consulting, speaking, food and travel. 3,777 general payment records and 121 research records were filed.

Common questions about Innocoll Pharmaceuticals Limited

How much has Innocoll Pharmaceuticals Limited paid US doctors?

Innocoll Pharmaceuticals Limited reported $14,871,464 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $367,664 in general payments, $14,503,800 in research funding.

How does Innocoll Pharmaceuticals Limited rank among drug and device companies?

It ranks #392 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Innocoll Pharmaceuticals Limited mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.